![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CDKN2B |
Gene summary for CDKN2B |
![]() |
Gene information | Species | Human | Gene symbol | CDKN2B | Gene ID | 1030 |
Gene name | cyclin dependent kinase inhibitor 2B | |
Gene Alias | CDK4I | |
Cytomap | 9p21.3 | |
Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | K7PPU3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1030 | CDKN2B | CA_HPV_2 | Human | Cervix | CC | 3.25e-04 | 2.58e-01 | 0.0391 |
1030 | CDKN2B | CCI_1 | Human | Cervix | CC | 3.49e-05 | 6.26e-01 | 0.528 |
1030 | CDKN2B | CCI_2 | Human | Cervix | CC | 1.50e-05 | 8.07e-01 | 0.5249 |
1030 | CDKN2B | CCI_3 | Human | Cervix | CC | 4.80e-07 | 5.92e-01 | 0.516 |
1030 | CDKN2B | Tumor | Human | Cervix | CC | 1.98e-19 | 4.77e-01 | 0.1241 |
1030 | CDKN2B | sample1 | Human | Cervix | CC | 2.91e-09 | 5.30e-01 | 0.0959 |
1030 | CDKN2B | sample3 | Human | Cervix | CC | 1.48e-29 | 5.72e-01 | 0.1387 |
1030 | CDKN2B | H2 | Human | Cervix | HSIL_HPV | 2.83e-04 | 3.04e-01 | 0.0632 |
1030 | CDKN2B | L1 | Human | Cervix | CC | 1.55e-04 | 4.04e-01 | 0.0802 |
1030 | CDKN2B | T1 | Human | Cervix | CC | 4.38e-24 | 6.30e-01 | 0.0918 |
1030 | CDKN2B | T3 | Human | Cervix | CC | 1.33e-22 | 4.96e-01 | 0.1389 |
1030 | CDKN2B | LZE7T | Human | Esophagus | ESCC | 2.41e-19 | 8.73e-01 | 0.0667 |
1030 | CDKN2B | LZE20T | Human | Esophagus | ESCC | 1.02e-17 | 9.56e-01 | 0.0662 |
1030 | CDKN2B | LZE21D1 | Human | Esophagus | HGIN | 3.76e-02 | 3.93e-01 | 0.0632 |
1030 | CDKN2B | LZE24T | Human | Esophagus | ESCC | 1.02e-28 | 1.30e+00 | 0.0596 |
1030 | CDKN2B | LZE21T | Human | Esophagus | ESCC | 3.45e-02 | 4.27e-01 | 0.0655 |
1030 | CDKN2B | P2T-E | Human | Esophagus | ESCC | 2.23e-46 | 1.03e+00 | 0.1177 |
1030 | CDKN2B | P4T-E | Human | Esophagus | ESCC | 5.65e-31 | 9.78e-01 | 0.1323 |
1030 | CDKN2B | P11T-E | Human | Esophagus | ESCC | 5.47e-03 | 3.65e-01 | 0.1426 |
1030 | CDKN2B | P15T-E | Human | Esophagus | ESCC | 4.87e-23 | 7.75e-01 | 0.1149 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075691 | Liver | HCC | cell aging | 73/7958 | 132/18723 | 2.00e-03 | 1.01e-02 | 73 |
GO:0000086 | Liver | HCC | G2/M transition of mitotic cell cycle | 75/7958 | 137/18723 | 2.52e-03 | 1.22e-02 | 75 |
GO:19038442 | Liver | HCC | regulation of cellular response to transforming growth factor beta stimulus | 72/7958 | 131/18723 | 2.65e-03 | 1.27e-02 | 72 |
GO:20000451 | Liver | HCC | regulation of G1/S transition of mitotic cell cycle | 77/7958 | 142/18723 | 3.13e-03 | 1.45e-02 | 77 |
GO:001701511 | Liver | HCC | regulation of transforming growth factor beta receptor signaling pathway | 70/7958 | 128/18723 | 3.56e-03 | 1.59e-02 | 70 |
GO:0071901 | Liver | HCC | negative regulation of protein serine/threonine kinase activity | 66/7958 | 120/18723 | 3.81e-03 | 1.68e-02 | 66 |
GO:0044839 | Liver | HCC | cell cycle G2/M phase transition | 79/7958 | 148/18723 | 4.82e-03 | 2.03e-02 | 79 |
GO:0031670 | Liver | HCC | cellular response to nutrient | 27/7958 | 45/18723 | 1.35e-02 | 4.80e-02 | 27 |
GO:00715594 | Lung | IAC | response to transforming growth factor beta | 60/2061 | 256/18723 | 9.50e-09 | 1.25e-06 | 60 |
GO:00447723 | Lung | IAC | mitotic cell cycle phase transition | 85/2061 | 424/18723 | 2.69e-08 | 3.20e-06 | 85 |
GO:00459368 | Lung | IAC | negative regulation of phosphate metabolic process | 87/2061 | 441/18723 | 4.00e-08 | 4.57e-06 | 87 |
GO:00105638 | Lung | IAC | negative regulation of phosphorus metabolic process | 87/2061 | 442/18723 | 4.46e-08 | 4.99e-06 | 87 |
GO:00715604 | Lung | IAC | cellular response to transforming growth factor beta stimulus | 57/2061 | 250/18723 | 6.17e-08 | 6.54e-06 | 57 |
GO:00719006 | Lung | IAC | regulation of protein serine/threonine kinase activity | 71/2061 | 359/18723 | 6.33e-07 | 3.72e-05 | 71 |
GO:00423268 | Lung | IAC | negative regulation of phosphorylation | 74/2061 | 385/18723 | 1.15e-06 | 6.18e-05 | 74 |
GO:00071794 | Lung | IAC | transforming growth factor beta receptor signaling pathway | 45/2061 | 198/18723 | 1.60e-06 | 7.93e-05 | 45 |
GO:00019338 | Lung | IAC | negative regulation of protein phosphorylation | 66/2061 | 342/18723 | 3.72e-06 | 1.55e-04 | 66 |
GO:00000823 | Lung | IAC | G1/S transition of mitotic cell cycle | 46/2061 | 214/18723 | 6.13e-06 | 2.29e-04 | 46 |
GO:00300998 | Lung | IAC | myeloid cell differentiation | 70/2061 | 381/18723 | 1.12e-05 | 3.45e-04 | 70 |
GO:00448433 | Lung | IAC | cell cycle G1/S phase transition | 49/2061 | 241/18723 | 1.54e-05 | 4.49e-04 | 49 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa052226 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa041106 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa0421815 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0522213 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa0411013 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa0516625 | Cervix | HSIL_HPV | Human T-cell leukemia virus 1 infection | 25/459 | 222/8465 | 3.95e-04 | 3.49e-03 | 2.82e-03 | 25 |
hsa0522222 | Cervix | HSIL_HPV | Small cell lung cancer | 13/459 | 92/8465 | 1.30e-03 | 9.51e-03 | 7.68e-03 | 13 |
hsa0516635 | Cervix | HSIL_HPV | Human T-cell leukemia virus 1 infection | 25/459 | 222/8465 | 3.95e-04 | 3.49e-03 | 2.82e-03 | 25 |
hsa0522232 | Cervix | HSIL_HPV | Small cell lung cancer | 13/459 | 92/8465 | 1.30e-03 | 9.51e-03 | 7.68e-03 | 13 |
hsa052039 | Esophagus | HGIN | Viral carcinogenesis | 53/1383 | 204/8465 | 2.58e-04 | 2.71e-03 | 2.15e-03 | 53 |
hsa0421828 | Esophagus | HGIN | Cellular senescence | 42/1383 | 156/8465 | 4.94e-04 | 5.03e-03 | 4.00e-03 | 42 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa041109 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa0520315 | Esophagus | HGIN | Viral carcinogenesis | 53/1383 | 204/8465 | 2.58e-04 | 2.71e-03 | 2.15e-03 | 53 |
hsa04218111 | Esophagus | HGIN | Cellular senescence | 42/1383 | 156/8465 | 4.94e-04 | 5.03e-03 | 4.00e-03 | 42 |
hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0411016 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDKN2B | SNV | Missense_Mutation | c.82G>C | p.Glu28Gln | p.E28Q | P42772 | protein_coding | tolerated(0.41) | benign(0.218) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CDKN2B | SNV | Missense_Mutation | novel | c.209C>T | p.Ala70Val | p.A70V | P42772 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDKN2B | SNV | Missense_Mutation | novel | c.24N>A | p.Met8Ile | p.M8I | P42772 | protein_coding | tolerated_low_confidence(0.36) | benign(0.01) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CDKN2B | SNV | Missense_Mutation | novel | c.311N>T | p.Ala104Val | p.A104V | P42772 | protein_coding | deleterious(0) | possibly_damaging(0.694) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDKN2B | SNV | Missense_Mutation | c.367C>T | p.Arg123Trp | p.R123W | P42772 | protein_coding | deleterious(0.01) | possibly_damaging(0.683) | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
CDKN2B | SNV | Missense_Mutation | novel | c.133N>A | p.Arg45Ser | p.R45S | P42772 | protein_coding | tolerated(0.53) | benign(0.009) | TCGA-2Y-A9H3-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
CDKN2B | deletion | In_Frame_Del | novel | c.374_394delNNNNNNNNNNNNNNNNNNNNN | p.His125_Tyr131del | p.H125_Y131del | P42772 | protein_coding | TCGA-98-8021-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
CDKN2B | SNV | Missense_Mutation | c.179N>A | p.Arg60His | p.R60H | P42772 | protein_coding | tolerated(0.09) | benign(0) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | ||
CDKN2B | SNV | Missense_Mutation | novel | c.209C>T | p.Ala70Val | p.A70V | P42772 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1030 | CDKN2B | CLINICALLY ACTIONABLE, KINASE | PALBOCICLIB | PALBOCICLIB | 23898052 |
Page: 1 |